Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Influenza Vaccine with Topical Imiquimod in Immunocompromised Patients
NCT02960815Phase 2Completed
- Sponsor
- Lausanne University Hospital
- Start
- Nov 2016
- Primary completion
- Jun 2017
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of imiquimod in influenza (3 arms), sponsored by Lausanne University Hospital. Primary endpoint: Response to the vaccine at 21 days. Started Nov 2016; status: completed.
02
Drugs
imiquimod
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02960815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960815.